Anavex Life Sciences (AVXL) Cash from Operations Growth (5y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.90% |
| Sep 30, 2025 | -6.59% |
| Jun 30, 2025 | -25.25% |
| Mar 31, 2025 | -2.16% |
| Dec 31, 2024 | -16.18% |
| Sep 30, 2024 | -21.31% |
| Jun 30, 2024 | 7.14% |
| Mar 31, 2024 | -21.89% |
| Dec 31, 2023 | -11.96% |
| Sep 30, 2023 | -7.61% |
| Jun 30, 2023 | -29.66% |
| Mar 31, 2023 | -24.65% |
| Dec 31, 2022 | -9.86% |
| Sep 30, 2022 | -13.03% |
| Jun 30, 2022 | -18.85% |
| Mar 31, 2022 | -69.07% |
| Dec 31, 2021 | -2.11% |
| Sep 30, 2021 | -32.73% |
| Jun 30, 2021 | -27.60% |
| Mar 31, 2021 | -30.92% |
| Dec 31, 2020 | -19.37% |
| Sep 30, 2020 | -34.27% |
| Jun 30, 2020 | -23.11% |
| Mar 31, 2020 | -51.01% |
| Dec 31, 2019 | -52.55% |
| Sep 30, 2019 | -22.55% |
| Jun 30, 2019 | -50.86% |
| Mar 31, 2019 | -65.63% |
| Dec 31, 2018 | -57.08% |
| Sep 30, 2018 | -52.93% |
| Jun 30, 2018 | -130.36% |
| Mar 31, 2018 | -85.25% |
| Dec 31, 2017 | -94.05% |
| Sep 30, 2017 | -54.14% |
| Jun 30, 2017 | -65.61% |
| Mar 31, 2017 | -43.62% |
| Dec 31, 2016 | -23.72% |
| Sep 30, 2016 | -15.09% |
| Jun 30, 2016 | -13.02% |
| Mar 31, 2016 | -26.43% |
| Dec 31, 2015 | -24.54% |
| Sep 30, 2015 | 2.94% |